nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—VEGFA—brain cancer	0.287	0.542	CbGaD
Vandetanib—EGFR—brain cancer	0.242	0.458	CbGaD
Vandetanib—ABCC1—Etoposide—brain cancer	0.0238	0.256	CbGbCtD
Vandetanib—ABCG2—Carboplatin—brain cancer	0.019	0.204	CbGbCtD
Vandetanib—CYP3A4—Temozolomide—brain cancer	0.0167	0.18	CbGbCtD
Vandetanib—ABCG2—Etoposide—brain cancer	0.0159	0.171	CbGbCtD
Vandetanib—CYP3A4—Lomustine—brain cancer	0.0142	0.153	CbGbCtD
Vandetanib—CYP3A4—Etoposide—brain cancer	0.00344	0.0369	CbGbCtD
Vandetanib—Afatinib—ERBB2—brain cancer	0.00221	0.348	CrCbGaD
Vandetanib—ERBB3—Podofilox—Etoposide—brain cancer	0.00157	0.566	CbGdCrCtD
Vandetanib—PLK4—Teniposide—Etoposide—brain cancer	0.0012	0.434	CbGdCrCtD
Vandetanib—Afatinib—EGFR—brain cancer	0.00105	0.165	CrCbGaD
Vandetanib—Bosutinib—ALK—brain cancer	0.00102	0.16	CrCbGaD
Vandetanib—Erlotinib—EGFR—brain cancer	0.00074	0.116	CrCbGaD
Vandetanib—MKNK1—telencephalon—brain cancer	0.000519	0.00482	CbGeAlD
Vandetanib—EPHA6—endocrine gland—brain cancer	0.000511	0.00475	CbGeAlD
Vandetanib—AXL—telencephalon—brain cancer	0.000511	0.00474	CbGeAlD
Vandetanib—PLK4—endocrine gland—brain cancer	0.000505	0.00469	CbGeAlD
Vandetanib—EPHA6—head—brain cancer	0.000505	0.00469	CbGeAlD
Vandetanib—ABL2—pituitary gland—brain cancer	0.000497	0.00462	CbGeAlD
Vandetanib—SLK—telencephalon—brain cancer	0.000492	0.00457	CbGeAlD
Vandetanib—FYN—telencephalon—brain cancer	0.000478	0.00444	CbGeAlD
Vandetanib—EPHA5—endocrine gland—brain cancer	0.000474	0.00441	CbGeAlD
Vandetanib—TYRO3—endocrine gland—brain cancer	0.000474	0.00441	CbGeAlD
Vandetanib—LYN—endocrine gland—brain cancer	0.000472	0.00438	CbGeAlD
Vandetanib—RIPK2—pituitary gland—brain cancer	0.00047	0.00437	CbGeAlD
Vandetanib—VEGFA—pituitary gland—brain cancer	0.000469	0.00436	CbGeAlD
Vandetanib—EPHA5—head—brain cancer	0.000468	0.00435	CbGeAlD
Vandetanib—TYRO3—head—brain cancer	0.000468	0.00435	CbGeAlD
Vandetanib—TEK—telencephalon—brain cancer	0.000467	0.00434	CbGeAlD
Vandetanib—MAP4K5—telencephalon—brain cancer	0.000467	0.00434	CbGeAlD
Vandetanib—FMO1—pituitary gland—brain cancer	0.000466	0.00433	CbGeAlD
Vandetanib—LYN—head—brain cancer	0.000466	0.00433	CbGeAlD
Vandetanib—BMPR1B—endocrine gland—brain cancer	0.000465	0.00432	CbGeAlD
Vandetanib—Gefitinib—EGFR—brain cancer	0.000463	0.0728	CrCbGaD
Vandetanib—EPHA6—central nervous system—brain cancer	0.000461	0.00428	CbGeAlD
Vandetanib—IRAK4—pituitary gland—brain cancer	0.000459	0.00427	CbGeAlD
Vandetanib—BMPR1B—head—brain cancer	0.000459	0.00426	CbGeAlD
Vandetanib—MAP3K19—head—brain cancer	0.000459	0.00426	CbGeAlD
Vandetanib—LTK—brain—brain cancer	0.000458	0.00425	CbGeAlD
Vandetanib—Bosutinib—EGFR—brain cancer	0.000456	0.0717	CrCbGaD
Vandetanib—RIPK2—medulla oblongata—brain cancer	0.000454	0.00422	CbGeAlD
Vandetanib—Sepsis—Carmustine—brain cancer	0.00045	0.00454	CcSEcCtD
Vandetanib—STK35—midbrain—brain cancer	0.00045	0.00418	CbGeAlD
Vandetanib—EPHB6—telencephalon—brain cancer	0.000446	0.00415	CbGeAlD
Vandetanib—IRAK4—medulla oblongata—brain cancer	0.000443	0.00412	CbGeAlD
Vandetanib—Haematuria—Procarbazine—brain cancer	0.000442	0.00446	CcSEcCtD
Vandetanib—Cellulitis—Etoposide—brain cancer	0.000441	0.00445	CcSEcCtD
Vandetanib—EPHA8—brain—brain cancer	0.000439	0.00408	CbGeAlD
Vandetanib—Epistaxis—Procarbazine—brain cancer	0.000438	0.00441	CcSEcCtD
Vandetanib—Blood creatinine increased—Hydroxyurea—brain cancer	0.000437	0.0044	CcSEcCtD
Vandetanib—MKNK1—gonad—brain cancer	0.000433	0.00402	CbGeAlD
Vandetanib—YES1—telencephalon—brain cancer	0.000431	0.00401	CbGeAlD
Vandetanib—MAP2K5—brainstem—brain cancer	0.00043	0.004	CbGeAlD
Vandetanib—EPHA5—central nervous system—brain cancer	0.000427	0.00397	CbGeAlD
Vandetanib—TYRO3—central nervous system—brain cancer	0.000427	0.00397	CbGeAlD
Vandetanib—AXL—gonad—brain cancer	0.000426	0.00396	CbGeAlD
Vandetanib—LYN—central nervous system—brain cancer	0.000425	0.00395	CbGeAlD
Vandetanib—MKNK1—pituitary gland—brain cancer	0.000423	0.00393	CbGeAlD
Vandetanib—Gefitinib—CYP2C9—brain cancer	0.000422	0.0664	CrCbGaD
Vandetanib—Body temperature increased—Carboplatin—brain cancer	0.000421	0.00424	CcSEcCtD
Vandetanib—BMPR1B—central nervous system—brain cancer	0.000419	0.00389	CbGeAlD
Vandetanib—MAP3K19—central nervous system—brain cancer	0.000419	0.00389	CbGeAlD
Vandetanib—Haemoglobin—Procarbazine—brain cancer	0.000419	0.00422	CcSEcCtD
Vandetanib—EPHA5—cerebellum—brain cancer	0.000418	0.00388	CbGeAlD
Vandetanib—TYRO3—cerebellum—brain cancer	0.000418	0.00388	CbGeAlD
Vandetanib—RET—pituitary gland—brain cancer	0.000417	0.00388	CbGeAlD
Vandetanib—FGR—pituitary gland—brain cancer	0.000417	0.00388	CbGeAlD
Vandetanib—Haemorrhage—Procarbazine—brain cancer	0.000417	0.0042	CcSEcCtD
Vandetanib—AXL—pituitary gland—brain cancer	0.000416	0.00386	CbGeAlD
Vandetanib—SRC—telencephalon—brain cancer	0.000415	0.00386	CbGeAlD
Vandetanib—RIPK2—midbrain—brain cancer	0.000415	0.00385	CbGeAlD
Vandetanib—Gastroenteritis—Temozolomide—brain cancer	0.000411	0.00414	CcSEcCtD
Vandetanib—BMPR1B—cerebellum—brain cancer	0.000409	0.0038	CbGeAlD
Vandetanib—MKNK1—medulla oblongata—brain cancer	0.000408	0.00379	CbGeAlD
Vandetanib—Decreased appetite—Lomustine—brain cancer	0.000405	0.00408	CcSEcCtD
Vandetanib—RIPK2—spinal cord—brain cancer	0.000405	0.00376	CbGeAlD
Vandetanib—VEGFA—spinal cord—brain cancer	0.000404	0.00375	CbGeAlD
Vandetanib—FLT3—endocrine gland—brain cancer	0.000403	0.00375	CbGeAlD
Vandetanib—FMO3—pituitary gland—brain cancer	0.000403	0.00375	CbGeAlD
Vandetanib—RET—medulla oblongata—brain cancer	0.000403	0.00374	CbGeAlD
Vandetanib—AXL—medulla oblongata—brain cancer	0.000401	0.00373	CbGeAlD
Vandetanib—SLK—pituitary gland—brain cancer	0.0004	0.00372	CbGeAlD
Vandetanib—ERBB3—midbrain—brain cancer	0.000397	0.00369	CbGeAlD
Vandetanib—IRAK4—spinal cord—brain cancer	0.000395	0.00367	CbGeAlD
Vandetanib—STK35—endocrine gland—brain cancer	0.000395	0.00367	CbGeAlD
Vandetanib—Pancreatitis—Hydroxyurea—brain cancer	0.000395	0.00398	CcSEcCtD
Vandetanib—STK35—head—brain cancer	0.00039	0.00362	CbGeAlD
Vandetanib—MAP4K5—gonad—brain cancer	0.00039	0.00362	CbGeAlD
Vandetanib—FYN—pituitary gland—brain cancer	0.000389	0.00362	CbGeAlD
Vandetanib—ERBB3—spinal cord—brain cancer	0.000387	0.0036	CbGeAlD
Vandetanib—SLK—medulla oblongata—brain cancer	0.000386	0.00359	CbGeAlD
Vandetanib—MAP2K5—telencephalon—brain cancer	0.000382	0.00355	CbGeAlD
Vandetanib—MAP4K5—pituitary gland—brain cancer	0.00038	0.00353	CbGeAlD
Vandetanib—TEK—pituitary gland—brain cancer	0.00038	0.00353	CbGeAlD
Vandetanib—Hyponatraemia—Carmustine—brain cancer	0.000378	0.00381	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Carmustine—brain cancer	0.000377	0.0038	CcSEcCtD
Vandetanib—Dysuria—Hydroxyurea—brain cancer	0.000377	0.00379	CcSEcCtD
Vandetanib—Neutropenia—Hydroxyurea—brain cancer	0.000377	0.00379	CcSEcCtD
Vandetanib—FYN—medulla oblongata—brain cancer	0.000376	0.00349	CbGeAlD
Vandetanib—MKNK1—midbrain—brain cancer	0.000373	0.00346	CbGeAlD
Vandetanib—Arrhythmia—Procarbazine—brain cancer	0.000372	0.00375	CcSEcCtD
Vandetanib—Body temperature increased—Lomustine—brain cancer	0.000368	0.00371	CcSEcCtD
Vandetanib—RET—midbrain—brain cancer	0.000368	0.00342	CbGeAlD
Vandetanib—Alopecia—Procarbazine—brain cancer	0.000368	0.00371	CcSEcCtD
Vandetanib—TEK—medulla oblongata—brain cancer	0.000367	0.00341	CbGeAlD
Vandetanib—MAP4K5—medulla oblongata—brain cancer	0.000367	0.00341	CbGeAlD
Vandetanib—AXL—midbrain—brain cancer	0.000367	0.00341	CbGeAlD
Vandetanib—FLT4—endocrine gland—brain cancer	0.000366	0.0034	CbGeAlD
Vandetanib—EPHA6—brain—brain cancer	0.000366	0.0034	CbGeAlD
Vandetanib—RIPK2—endocrine gland—brain cancer	0.000364	0.00338	CbGeAlD
Vandetanib—MKNK1—spinal cord—brain cancer	0.000364	0.00338	CbGeAlD
Vandetanib—EPHB6—pituitary gland—brain cancer	0.000363	0.00338	CbGeAlD
Vandetanib—FLT4—head—brain cancer	0.000362	0.00336	CbGeAlD
Vandetanib—FMO1—endocrine gland—brain cancer	0.000361	0.00336	CbGeAlD
Vandetanib—PLK4—brain—brain cancer	0.000361	0.00336	CbGeAlD
Vandetanib—YES1—gonad—brain cancer	0.00036	0.00334	CbGeAlD
Vandetanib—RIPK2—head—brain cancer	0.00036	0.00334	CbGeAlD
Vandetanib—RET—spinal cord—brain cancer	0.000359	0.00334	CbGeAlD
Vandetanib—Infestation—Hydroxyurea—brain cancer	0.000359	0.00362	CcSEcCtD
Vandetanib—Infestation NOS—Hydroxyurea—brain cancer	0.000359	0.00362	CcSEcCtD
Vandetanib—AXL—spinal cord—brain cancer	0.000358	0.00332	CbGeAlD
Vandetanib—FMO1—head—brain cancer	0.000357	0.00331	CbGeAlD
Vandetanib—STK10—gonad—brain cancer	0.000357	0.00331	CbGeAlD
Vandetanib—STK35—central nervous system—brain cancer	0.000356	0.00331	CbGeAlD
Vandetanib—FLT3—cerebellum—brain cancer	0.000355	0.0033	CbGeAlD
Vandetanib—SLK—midbrain—brain cancer	0.000353	0.00328	CbGeAlD
Vandetanib—IRAK4—head—brain cancer	0.000351	0.00326	CbGeAlD
Vandetanib—YES1—pituitary gland—brain cancer	0.000351	0.00326	CbGeAlD
Vandetanib—EPHB6—medulla oblongata—brain cancer	0.000351	0.00326	CbGeAlD
Vandetanib—Stomatitis—Hydroxyurea—brain cancer	0.00035	0.00353	CcSEcCtD
Vandetanib—ERBB3—endocrine gland—brain cancer	0.000349	0.00324	CbGeAlD
Vandetanib—Sepsis—Etoposide—brain cancer	0.000348	0.00351	CcSEcCtD
Vandetanib—STK35—cerebellum—brain cancer	0.000348	0.00323	CbGeAlD
Vandetanib—SRC—gonad—brain cancer	0.000346	0.00322	CbGeAlD
Vandetanib—SLK—spinal cord—brain cancer	0.000344	0.0032	CbGeAlD
Vandetanib—ERBB3—head—brain cancer	0.000344	0.0032	CbGeAlD
Vandetanib—FYN—midbrain—brain cancer	0.000343	0.00319	CbGeAlD
Vandetanib—Hypokalaemia—Carmustine—brain cancer	0.000343	0.00345	CcSEcCtD
Vandetanib—Tremor—Procarbazine—brain cancer	0.00034	0.00342	CcSEcCtD
Vandetanib—Hepatobiliary disease—Hydroxyurea—brain cancer	0.00034	0.00342	CcSEcCtD
Vandetanib—TYRO3—brain—brain cancer	0.000339	0.00315	CbGeAlD
Vandetanib—EPHA5—brain—brain cancer	0.000339	0.00315	CbGeAlD
Vandetanib—ABL2—cerebellum—brain cancer	0.000339	0.00315	CbGeAlD
Vandetanib—YES1—medulla oblongata—brain cancer	0.000339	0.00315	CbGeAlD
Vandetanib—Dehydration—Temozolomide—brain cancer	0.000339	0.00341	CcSEcCtD
Vandetanib—LYN—brain—brain cancer	0.000338	0.00314	CbGeAlD
Vandetanib—MAP4K5—midbrain—brain cancer	0.000335	0.00312	CbGeAlD
Vandetanib—TEK—midbrain—brain cancer	0.000335	0.00312	CbGeAlD
Vandetanib—FYN—spinal cord—brain cancer	0.000335	0.00311	CbGeAlD
Vandetanib—Dry skin—Temozolomide—brain cancer	0.000334	0.00336	CcSEcCtD
Vandetanib—MAP3K19—brain—brain cancer	0.000332	0.00309	CbGeAlD
Vandetanib—BMPR1B—brain—brain cancer	0.000332	0.00309	CbGeAlD
Vandetanib—ABL1—brainstem—brain cancer	0.000332	0.00308	CbGeAlD
Vandetanib—Hypokalaemia—Temozolomide—brain cancer	0.000331	0.00334	CcSEcCtD
Vandetanib—EGFR—cerebellum—brain cancer	0.000331	0.00308	CbGeAlD
Vandetanib—PDGFRB—telencephalon—brain cancer	0.00033	0.00307	CbGeAlD
Vandetanib—MKNK1—endocrine gland—brain cancer	0.000327	0.00304	CbGeAlD
Vandetanib—MAP4K5—spinal cord—brain cancer	0.000327	0.00304	CbGeAlD
Vandetanib—TEK—spinal cord—brain cancer	0.000327	0.00304	CbGeAlD
Vandetanib—FMO1—central nervous system—brain cancer	0.000326	0.00303	CbGeAlD
Vandetanib—Dysphagia—Carmustine—brain cancer	0.000326	0.00328	CcSEcCtD
Vandetanib—Haemoglobin—Hydroxyurea—brain cancer	0.000324	0.00326	CcSEcCtD
Vandetanib—FGR—endocrine gland—brain cancer	0.000323	0.003	CbGeAlD
Vandetanib—RET—endocrine gland—brain cancer	0.000323	0.003	CbGeAlD
Vandetanib—MKNK1—head—brain cancer	0.000323	0.003	CbGeAlD
Vandetanib—Haemorrhage—Hydroxyurea—brain cancer	0.000322	0.00325	CcSEcCtD
Vandetanib—AXL—endocrine gland—brain cancer	0.000322	0.00299	CbGeAlD
Vandetanib—Alanine aminotransferase increased—Temozolomide—brain cancer	0.000321	0.00324	CcSEcCtD
Vandetanib—RIPK2—cerebellum—brain cancer	0.000321	0.00298	CbGeAlD
Vandetanib—IRAK4—central nervous system—brain cancer	0.000321	0.00298	CbGeAlD
Vandetanib—EPHB6—midbrain—brain cancer	0.000321	0.00298	CbGeAlD
Vandetanib—VEGFA—cerebellum—brain cancer	0.00032	0.00297	CbGeAlD
Vandetanib—FGR—head—brain cancer	0.000319	0.00297	CbGeAlD
Vandetanib—RET—head—brain cancer	0.000319	0.00297	CbGeAlD
Vandetanib—Loss of consciousness—Procarbazine—brain cancer	0.000319	0.00321	CcSEcCtD
Vandetanib—AXL—head—brain cancer	0.000318	0.00295	CbGeAlD
Vandetanib—Cough—Procarbazine—brain cancer	0.000316	0.00319	CcSEcCtD
Vandetanib—Dysphagia—Temozolomide—brain cancer	0.000315	0.00317	CcSEcCtD
Vandetanib—ERBB3—central nervous system—brain cancer	0.000314	0.00292	CbGeAlD
Vandetanib—Convulsion—Procarbazine—brain cancer	0.000314	0.00317	CcSEcCtD
Vandetanib—IRAK4—cerebellum—brain cancer	0.000313	0.00291	CbGeAlD
Vandetanib—Hypertension—Procarbazine—brain cancer	0.000313	0.00315	CcSEcCtD
Vandetanib—EPHB6—spinal cord—brain cancer	0.000313	0.00291	CbGeAlD
Vandetanib—FMO3—endocrine gland—brain cancer	0.000312	0.0029	CbGeAlD
Vandetanib—KDR—pituitary gland—brain cancer	0.000311	0.00289	CbGeAlD
Vandetanib—MAP2K5—pituitary gland—brain cancer	0.000311	0.00289	CbGeAlD
Vandetanib—YES1—midbrain—brain cancer	0.00031	0.00288	CbGeAlD
Vandetanib—Arthralgia—Procarbazine—brain cancer	0.000309	0.00311	CcSEcCtD
Vandetanib—FMO3—head—brain cancer	0.000308	0.00286	CbGeAlD
Vandetanib—Anxiety—Procarbazine—brain cancer	0.000308	0.0031	CcSEcCtD
Vandetanib—ERBB3—cerebellum—brain cancer	0.000307	0.00285	CbGeAlD
Vandetanib—Neutropenia—Carmustine—brain cancer	0.000304	0.00307	CcSEcCtD
Vandetanib—Bronchitis—Temozolomide—brain cancer	0.000303	0.00305	CcSEcCtD
Vandetanib—YES1—spinal cord—brain cancer	0.000302	0.00281	CbGeAlD
Vandetanib—Dry mouth—Procarbazine—brain cancer	0.000302	0.00304	CcSEcCtD
Vandetanib—FYN—endocrine gland—brain cancer	0.000301	0.0028	CbGeAlD
Vandetanib—KDR—medulla oblongata—brain cancer	0.0003	0.00279	CbGeAlD
Vandetanib—MAP2K5—medulla oblongata—brain cancer	0.0003	0.00279	CbGeAlD
Vandetanib—Cardiac failure—Etoposide—brain cancer	0.000298	0.00301	CcSEcCtD
Vandetanib—FYN—head—brain cancer	0.000298	0.00276	CbGeAlD
Vandetanib—Vomiting—Lomustine—brain cancer	0.000296	0.00299	CcSEcCtD
Vandetanib—Oedema—Procarbazine—brain cancer	0.000296	0.00298	CcSEcCtD
Vandetanib—MKNK1—central nervous system—brain cancer	0.000295	0.00274	CbGeAlD
Vandetanib—TEK—endocrine gland—brain cancer	0.000295	0.00274	CbGeAlD
Vandetanib—MAP4K5—endocrine gland—brain cancer	0.000295	0.00274	CbGeAlD
Vandetanib—ABL1—telencephalon—brain cancer	0.000294	0.00274	CbGeAlD
Vandetanib—Dysuria—Temozolomide—brain cancer	0.000294	0.00296	CcSEcCtD
Vandetanib—Neutropenia—Temozolomide—brain cancer	0.000294	0.00296	CcSEcCtD
Vandetanib—Infection—Procarbazine—brain cancer	0.000294	0.00296	CcSEcCtD
Vandetanib—Hyperglycaemia—Carmustine—brain cancer	0.000294	0.00296	CcSEcCtD
Vandetanib—Angiopathy—Hydroxyurea—brain cancer	0.000292	0.00295	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Temozolomide—brain cancer	0.000292	0.00295	CcSEcCtD
Vandetanib—Pneumonia—Carmustine—brain cancer	0.000292	0.00294	CcSEcCtD
Vandetanib—RET—central nervous system—brain cancer	0.000291	0.00271	CbGeAlD
Vandetanib—FGR—central nervous system—brain cancer	0.000291	0.00271	CbGeAlD
Vandetanib—MAP4K5—head—brain cancer	0.000291	0.0027	CbGeAlD
Vandetanib—TEK—head—brain cancer	0.000291	0.0027	CbGeAlD
Vandetanib—SRC—spinal cord—brain cancer	0.000291	0.0027	CbGeAlD
Vandetanib—Pollakiuria—Temozolomide—brain cancer	0.000291	0.00293	CcSEcCtD
Vandetanib—AXL—central nervous system—brain cancer	0.00029	0.0027	CbGeAlD
Vandetanib—Thrombocytopenia—Procarbazine—brain cancer	0.00029	0.00292	CcSEcCtD
Vandetanib—Depression—Carmustine—brain cancer	0.000289	0.00292	CcSEcCtD
Vandetanib—MKNK1—cerebellum—brain cancer	0.000288	0.00268	CbGeAlD
Vandetanib—Photosensitivity reaction—Temozolomide—brain cancer	0.000287	0.00289	CcSEcCtD
Vandetanib—Renal failure—Carmustine—brain cancer	0.000285	0.00288	CcSEcCtD
Vandetanib—Alopecia—Hydroxyurea—brain cancer	0.000285	0.00287	CcSEcCtD
Vandetanib—RET—cerebellum—brain cancer	0.000285	0.00265	CbGeAlD
Vandetanib—Weight decreased—Temozolomide—brain cancer	0.000285	0.00287	CcSEcCtD
Vandetanib—Hyperglycaemia—Temozolomide—brain cancer	0.000284	0.00286	CcSEcCtD
Vandetanib—AXL—cerebellum—brain cancer	0.000284	0.00264	CbGeAlD
Vandetanib—Stomatitis—Carmustine—brain cancer	0.000283	0.00285	CcSEcCtD
Vandetanib—STK35—brain—brain cancer	0.000283	0.00263	CbGeAlD
Vandetanib—Urinary tract infection—Carmustine—brain cancer	0.000282	0.00284	CcSEcCtD
Vandetanib—Pneumonia—Temozolomide—brain cancer	0.000282	0.00284	CcSEcCtD
Vandetanib—FMO3—central nervous system—brain cancer	0.000281	0.00261	CbGeAlD
Vandetanib—Infestation—Temozolomide—brain cancer	0.000281	0.00283	CcSEcCtD
Vandetanib—Infestation NOS—Temozolomide—brain cancer	0.000281	0.00283	CcSEcCtD
Vandetanib—Depression—Temozolomide—brain cancer	0.00028	0.00282	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Temozolomide—brain cancer	0.000278	0.0028	CcSEcCtD
Vandetanib—EPHB6—head—brain cancer	0.000278	0.00258	CbGeAlD
Vandetanib—Cardiac arrest—Etoposide—brain cancer	0.000277	0.00279	CcSEcCtD
Vandetanib—Nausea—Lomustine—brain cancer	0.000277	0.00279	CcSEcCtD
Vandetanib—PDGFRB—gonad—brain cancer	0.000276	0.00256	CbGeAlD
Vandetanib—ABL2—brain—brain cancer	0.000275	0.00256	CbGeAlD
Vandetanib—MAP2K5—midbrain—brain cancer	0.000274	0.00255	CbGeAlD
Vandetanib—KDR—midbrain—brain cancer	0.000274	0.00255	CbGeAlD
Vandetanib—Stomatitis—Temozolomide—brain cancer	0.000273	0.00276	CcSEcCtD
Vandetanib—SLK—cerebellum—brain cancer	0.000273	0.00254	CbGeAlD
Vandetanib—Urinary tract infection—Temozolomide—brain cancer	0.000273	0.00275	CcSEcCtD
Vandetanib—YES1—endocrine gland—brain cancer	0.000272	0.00253	CbGeAlD
Vandetanib—FYN—central nervous system—brain cancer	0.000272	0.00252	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Procarbazine—brain cancer	0.00027	0.00272	CcSEcCtD
Vandetanib—STK10—endocrine gland—brain cancer	0.00027	0.0025	CbGeAlD
Vandetanib—PDGFRB—pituitary gland—brain cancer	0.000269	0.0025	CbGeAlD
Vandetanib—EGFR—brain—brain cancer	0.000269	0.0025	CbGeAlD
Vandetanib—YES1—head—brain cancer	0.000269	0.0025	CbGeAlD
Vandetanib—Insomnia—Procarbazine—brain cancer	0.000268	0.0027	CcSEcCtD
Vandetanib—MAP2K5—spinal cord—brain cancer	0.000267	0.00248	CbGeAlD
Vandetanib—KDR—spinal cord—brain cancer	0.000267	0.00248	CbGeAlD
Vandetanib—STK10—head—brain cancer	0.000266	0.00247	CbGeAlD
Vandetanib—Paraesthesia—Procarbazine—brain cancer	0.000266	0.00268	CcSEcCtD
Vandetanib—FYN—cerebellum—brain cancer	0.000266	0.00247	CbGeAlD
Vandetanib—MAP4K5—central nervous system—brain cancer	0.000265	0.00247	CbGeAlD
Vandetanib—TEK—central nervous system—brain cancer	0.000265	0.00247	CbGeAlD
Vandetanib—Hepatobiliary disease—Temozolomide—brain cancer	0.000265	0.00267	CcSEcCtD
Vandetanib—Sinusitis—Temozolomide—brain cancer	0.000263	0.00265	CcSEcCtD
Vandetanib—FLT4—brain—brain cancer	0.000262	0.00243	CbGeAlD
Vandetanib—Haemoglobin—Carmustine—brain cancer	0.000262	0.00264	CcSEcCtD
Vandetanib—SRC—endocrine gland—brain cancer	0.000262	0.00243	CbGeAlD
Vandetanib—RIPK2—brain—brain cancer	0.000261	0.00242	CbGeAlD
Vandetanib—Haemorrhage—Carmustine—brain cancer	0.000261	0.00263	CcSEcCtD
Vandetanib—VEGFA—brain—brain cancer	0.00026	0.00241	CbGeAlD
Vandetanib—PDGFRB—medulla oblongata—brain cancer	0.00026	0.00241	CbGeAlD
Vandetanib—MAP4K5—cerebellum—brain cancer	0.000259	0.00241	CbGeAlD
Vandetanib—TEK—cerebellum—brain cancer	0.000259	0.00241	CbGeAlD
Vandetanib—FMO1—brain—brain cancer	0.000259	0.0024	CbGeAlD
Vandetanib—SRC—head—brain cancer	0.000258	0.0024	CbGeAlD
Vandetanib—Decreased appetite—Procarbazine—brain cancer	0.000257	0.00259	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Etoposide—brain cancer	0.000257	0.00259	CcSEcCtD
Vandetanib—Fatigue—Procarbazine—brain cancer	0.000255	0.00257	CcSEcCtD
Vandetanib—IRAK4—brain—brain cancer	0.000255	0.00236	CbGeAlD
Vandetanib—EPHB6—central nervous system—brain cancer	0.000254	0.00236	CbGeAlD
Vandetanib—Haemoglobin—Temozolomide—brain cancer	0.000253	0.00255	CcSEcCtD
Vandetanib—Pain—Procarbazine—brain cancer	0.000253	0.00255	CcSEcCtD
Vandetanib—Constipation—Procarbazine—brain cancer	0.000253	0.00255	CcSEcCtD
Vandetanib—Haemorrhage—Temozolomide—brain cancer	0.000252	0.00254	CcSEcCtD
Vandetanib—Dysphagia—Etoposide—brain cancer	0.000252	0.00254	CcSEcCtD
Vandetanib—Visual impairment—Carmustine—brain cancer	0.000251	0.00253	CcSEcCtD
Vandetanib—ERBB3—brain—brain cancer	0.000249	0.00232	CbGeAlD
Vandetanib—Urinary tract disorder—Temozolomide—brain cancer	0.000249	0.00251	CcSEcCtD
Vandetanib—EPHB6—cerebellum—brain cancer	0.000248	0.0023	CbGeAlD
Vandetanib—Bronchospasm—Etoposide—brain cancer	0.000248	0.0025	CcSEcCtD
Vandetanib—Urethral disorder—Temozolomide—brain cancer	0.000247	0.00249	CcSEcCtD
Vandetanib—ABL1—gonad—brain cancer	0.000246	0.00228	CbGeAlD
Vandetanib—YES1—central nervous system—brain cancer	0.000245	0.00228	CbGeAlD
Vandetanib—Eye disorder—Carmustine—brain cancer	0.000244	0.00245	CcSEcCtD
Vandetanib—Convulsion—Hydroxyurea—brain cancer	0.000243	0.00245	CcSEcCtD
Vandetanib—STK10—central nervous system—brain cancer	0.000243	0.00226	CbGeAlD
Vandetanib—Visual impairment—Temozolomide—brain cancer	0.000243	0.00245	CcSEcCtD
Vandetanib—Gastrointestinal pain—Procarbazine—brain cancer	0.000242	0.00244	CcSEcCtD
Vandetanib—MAP2K5—endocrine gland—brain cancer	0.000241	0.00224	CbGeAlD
Vandetanib—KDR—endocrine gland—brain cancer	0.000241	0.00224	CbGeAlD
Vandetanib—ABL1—pituitary gland—brain cancer	0.00024	0.00223	CbGeAlD
Vandetanib—YES1—cerebellum—brain cancer	0.00024	0.00223	CbGeAlD
Vandetanib—Erythema multiforme—Temozolomide—brain cancer	0.000238	0.0024	CcSEcCtD
Vandetanib—KDR—head—brain cancer	0.000238	0.00221	CbGeAlD
Vandetanib—MAP2K5—head—brain cancer	0.000238	0.00221	CbGeAlD
Vandetanib—STK10—cerebellum—brain cancer	0.000237	0.00221	CbGeAlD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000237	0.00239	CcSEcCtD
Vandetanib—PDGFRB—midbrain—brain cancer	0.000237	0.0022	CbGeAlD
Vandetanib—SRC—central nervous system—brain cancer	0.000236	0.00219	CbGeAlD
Vandetanib—Neutropenia—Etoposide—brain cancer	0.000235	0.00237	CcSEcCtD
Vandetanib—Eye disorder—Temozolomide—brain cancer	0.000235	0.00237	CcSEcCtD
Vandetanib—MKNK1—brain—brain cancer	0.000234	0.00218	CbGeAlD
Vandetanib—Abdominal pain—Procarbazine—brain cancer	0.000234	0.00236	CcSEcCtD
Vandetanib—Body temperature increased—Procarbazine—brain cancer	0.000234	0.00236	CcSEcCtD
Vandetanib—Cardiac disorder—Temozolomide—brain cancer	0.000234	0.00236	CcSEcCtD
Vandetanib—Arrhythmia—Carmustine—brain cancer	0.000233	0.00235	CcSEcCtD
Vandetanib—PDGFRB—spinal cord—brain cancer	0.000231	0.00215	CbGeAlD
Vandetanib—ABL1—medulla oblongata—brain cancer	0.000231	0.00215	CbGeAlD
Vandetanib—RET—brain—brain cancer	0.000231	0.00215	CbGeAlD
Vandetanib—FGR—brain—brain cancer	0.000231	0.00215	CbGeAlD
Vandetanib—SRC—cerebellum—brain cancer	0.000231	0.00214	CbGeAlD
Vandetanib—AXL—brain—brain cancer	0.00023	0.00214	CbGeAlD
Vandetanib—Alopecia—Carmustine—brain cancer	0.00023	0.00232	CcSEcCtD
Vandetanib—Oedema—Hydroxyurea—brain cancer	0.000229	0.00231	CcSEcCtD
Vandetanib—Angiopathy—Temozolomide—brain cancer	0.000228	0.0023	CcSEcCtD
Vandetanib—Mental disorder—Carmustine—brain cancer	0.000228	0.0023	CcSEcCtD
Vandetanib—Infection—Hydroxyurea—brain cancer	0.000228	0.00229	CcSEcCtD
Vandetanib—Mediastinal disorder—Temozolomide—brain cancer	0.000227	0.00229	CcSEcCtD
Vandetanib—Malnutrition—Carmustine—brain cancer	0.000227	0.00229	CcSEcCtD
Vandetanib—Pneumonia—Etoposide—brain cancer	0.000226	0.00228	CcSEcCtD
Vandetanib—Nervous system disorder—Hydroxyurea—brain cancer	0.000225	0.00226	CcSEcCtD
Vandetanib—Infestation—Etoposide—brain cancer	0.000224	0.00226	CcSEcCtD
Vandetanib—Infestation NOS—Etoposide—brain cancer	0.000224	0.00226	CcSEcCtD
Vandetanib—ABCC1—telencephalon—brain cancer	0.000224	0.00208	CbGeAlD
Vandetanib—Thrombocytopenia—Hydroxyurea—brain cancer	0.000224	0.00226	CcSEcCtD
Vandetanib—FMO3—brain—brain cancer	0.000223	0.00208	CbGeAlD
Vandetanib—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000223	0.00224	CcSEcCtD
Vandetanib—Alopecia—Temozolomide—brain cancer	0.000223	0.00224	CcSEcCtD
Vandetanib—Skin disorder—Hydroxyurea—brain cancer	0.000222	0.00224	CcSEcCtD
Vandetanib—SLK—brain—brain cancer	0.000222	0.00206	CbGeAlD
Vandetanib—Renal failure—Etoposide—brain cancer	0.000221	0.00222	CcSEcCtD
Vandetanib—Mental disorder—Temozolomide—brain cancer	0.000221	0.00222	CcSEcCtD
Vandetanib—Malnutrition—Temozolomide—brain cancer	0.000219	0.00221	CcSEcCtD
Vandetanib—Stomatitis—Etoposide—brain cancer	0.000219	0.0022	CcSEcCtD
Vandetanib—ORM1—spinal cord—brain cancer	0.000217	0.00202	CbGeAlD
Vandetanib—KDR—central nervous system—brain cancer	0.000217	0.00202	CbGeAlD
Vandetanib—MAP2K5—central nervous system—brain cancer	0.000217	0.00202	CbGeAlD
Vandetanib—FYN—brain—brain cancer	0.000216	0.002	CbGeAlD
Vandetanib—Dysgeusia—Temozolomide—brain cancer	0.000215	0.00216	CcSEcCtD
Vandetanib—Vision blurred—Carmustine—brain cancer	0.000214	0.00215	CcSEcCtD
Vandetanib—Tremor—Carmustine—brain cancer	0.000213	0.00214	CcSEcCtD
Vandetanib—Asthenia—Procarbazine—brain cancer	0.000212	0.00214	CcSEcCtD
Vandetanib—Hepatobiliary disease—Etoposide—brain cancer	0.000212	0.00214	CcSEcCtD
Vandetanib—KDR—cerebellum—brain cancer	0.000212	0.00197	CbGeAlD
Vandetanib—MAP2K5—cerebellum—brain cancer	0.000212	0.00197	CbGeAlD
Vandetanib—ABL1—midbrain—brain cancer	0.000211	0.00196	CbGeAlD
Vandetanib—MAP4K5—brain—brain cancer	0.000211	0.00196	CbGeAlD
Vandetanib—TEK—brain—brain cancer	0.000211	0.00196	CbGeAlD
Vandetanib—Pruritus—Procarbazine—brain cancer	0.000209	0.00211	CcSEcCtD
Vandetanib—PDGFRB—endocrine gland—brain cancer	0.000208	0.00194	CbGeAlD
Vandetanib—Vision blurred—Temozolomide—brain cancer	0.000207	0.00208	CcSEcCtD
Vandetanib—ABL1—spinal cord—brain cancer	0.000206	0.00192	CbGeAlD
Vandetanib—PDGFRB—head—brain cancer	0.000206	0.00191	CbGeAlD
Vandetanib—Tremor—Temozolomide—brain cancer	0.000205	0.00207	CcSEcCtD
Vandetanib—Dyspnoea—Hydroxyurea—brain cancer	0.000204	0.00206	CcSEcCtD
Vandetanib—Diarrhoea—Procarbazine—brain cancer	0.000202	0.00204	CcSEcCtD
Vandetanib—Dyspepsia—Hydroxyurea—brain cancer	0.000202	0.00203	CcSEcCtD
Vandetanib—EPHB6—brain—brain cancer	0.000201	0.00187	CbGeAlD
Vandetanib—Decreased appetite—Hydroxyurea—brain cancer	0.000199	0.00201	CcSEcCtD
Vandetanib—Urinary tract disorder—Etoposide—brain cancer	0.000199	0.00201	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000198	0.00199	CcSEcCtD
Vandetanib—Urethral disorder—Etoposide—brain cancer	0.000198	0.00199	CcSEcCtD
Vandetanib—Fatigue—Hydroxyurea—brain cancer	0.000197	0.00199	CcSEcCtD
Vandetanib—Convulsion—Carmustine—brain cancer	0.000197	0.00198	CcSEcCtD
Vandetanib—Hypertension—Carmustine—brain cancer	0.000196	0.00197	CcSEcCtD
Vandetanib—Constipation—Hydroxyurea—brain cancer	0.000196	0.00197	CcSEcCtD
Vandetanib—Pain—Hydroxyurea—brain cancer	0.000196	0.00197	CcSEcCtD
Vandetanib—Dizziness—Procarbazine—brain cancer	0.000196	0.00197	CcSEcCtD
Vandetanib—ORM1—endocrine gland—brain cancer	0.000195	0.00182	CbGeAlD
Vandetanib—YES1—brain—brain cancer	0.000195	0.00181	CbGeAlD
Vandetanib—Chest pain—Carmustine—brain cancer	0.000193	0.00195	CcSEcCtD
Vandetanib—STK10—brain—brain cancer	0.000193	0.00179	CbGeAlD
Vandetanib—Anxiety—Carmustine—brain cancer	0.000192	0.00194	CcSEcCtD
Vandetanib—Cough—Temozolomide—brain cancer	0.000191	0.00193	CcSEcCtD
Vandetanib—Erythema multiforme—Etoposide—brain cancer	0.000191	0.00192	CcSEcCtD
Vandetanib—Convulsion—Temozolomide—brain cancer	0.00019	0.00191	CcSEcCtD
Vandetanib—Hypertension—Temozolomide—brain cancer	0.000189	0.00191	CcSEcCtD
Vandetanib—Eye disorder—Etoposide—brain cancer	0.000188	0.0019	CcSEcCtD
Vandetanib—Vomiting—Procarbazine—brain cancer	0.000188	0.0019	CcSEcCtD
Vandetanib—PDGFRB—central nervous system—brain cancer	0.000188	0.00174	CbGeAlD
Vandetanib—SRC—brain—brain cancer	0.000187	0.00174	CbGeAlD
Vandetanib—Cardiac disorder—Etoposide—brain cancer	0.000187	0.00188	CcSEcCtD
Vandetanib—Arthralgia—Temozolomide—brain cancer	0.000187	0.00188	CcSEcCtD
Vandetanib—Rash—Procarbazine—brain cancer	0.000187	0.00188	CcSEcCtD
Vandetanib—Dermatitis—Procarbazine—brain cancer	0.000186	0.00188	CcSEcCtD
Vandetanib—Anxiety—Temozolomide—brain cancer	0.000186	0.00187	CcSEcCtD
Vandetanib—ABL1—endocrine gland—brain cancer	0.000186	0.00173	CbGeAlD
Vandetanib—ABCG2—telencephalon—brain cancer	0.000186	0.00173	CbGeAlD
Vandetanib—Headache—Procarbazine—brain cancer	0.000185	0.00187	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000185	0.00187	CcSEcCtD
Vandetanib—Oedema—Carmustine—brain cancer	0.000185	0.00187	CcSEcCtD
Vandetanib—Infection—Carmustine—brain cancer	0.000184	0.00185	CcSEcCtD
Vandetanib—PDGFRB—cerebellum—brain cancer	0.000184	0.00171	CbGeAlD
Vandetanib—ABL1—head—brain cancer	0.000183	0.0017	CbGeAlD
Vandetanib—Angiopathy—Etoposide—brain cancer	0.000183	0.00184	CcSEcCtD
Vandetanib—ABCC1—pituitary gland—brain cancer	0.000183	0.0017	CbGeAlD
Vandetanib—Dry mouth—Temozolomide—brain cancer	0.000183	0.00184	CcSEcCtD
Vandetanib—Mediastinal disorder—Etoposide—brain cancer	0.000182	0.00183	CcSEcCtD
Vandetanib—Thrombocytopenia—Carmustine—brain cancer	0.000181	0.00183	CcSEcCtD
Vandetanib—Body temperature increased—Hydroxyurea—brain cancer	0.000181	0.00182	CcSEcCtD
Vandetanib—Oedema—Temozolomide—brain cancer	0.000179	0.0018	CcSEcCtD
Vandetanib—Alopecia—Etoposide—brain cancer	0.000178	0.00179	CcSEcCtD
Vandetanib—Infection—Temozolomide—brain cancer	0.000178	0.00179	CcSEcCtD
Vandetanib—ORM1—central nervous system—brain cancer	0.000176	0.00164	CbGeAlD
Vandetanib—Nausea—Procarbazine—brain cancer	0.000176	0.00177	CcSEcCtD
Vandetanib—Nervous system disorder—Temozolomide—brain cancer	0.000175	0.00177	CcSEcCtD
Vandetanib—Thrombocytopenia—Temozolomide—brain cancer	0.000175	0.00177	CcSEcCtD
Vandetanib—Skin disorder—Temozolomide—brain cancer	0.000174	0.00175	CcSEcCtD
Vandetanib—MAP2K5—brain—brain cancer	0.000172	0.0016	CbGeAlD
Vandetanib—KDR—brain—brain cancer	0.000172	0.0016	CbGeAlD
Vandetanib—Dysgeusia—Etoposide—brain cancer	0.000172	0.00173	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Carmustine—brain cancer	0.000169	0.0017	CcSEcCtD
Vandetanib—Muscle spasms—Etoposide—brain cancer	0.000169	0.0017	CcSEcCtD
Vandetanib—Insomnia—Carmustine—brain cancer	0.000167	0.00169	CcSEcCtD
Vandetanib—ABL1—central nervous system—brain cancer	0.000167	0.00155	CbGeAlD
Vandetanib—Paraesthesia—Carmustine—brain cancer	0.000166	0.00168	CcSEcCtD
Vandetanib—Dyspnoea—Carmustine—brain cancer	0.000165	0.00166	CcSEcCtD
Vandetanib—Asthenia—Hydroxyurea—brain cancer	0.000164	0.00166	CcSEcCtD
Vandetanib—ABL1—cerebellum—brain cancer	0.000164	0.00152	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000163	0.00164	CcSEcCtD
Vandetanib—Insomnia—Temozolomide—brain cancer	0.000162	0.00163	CcSEcCtD
Vandetanib—Decreased appetite—Carmustine—brain cancer	0.000161	0.00162	CcSEcCtD
Vandetanib—Paraesthesia—Temozolomide—brain cancer	0.000161	0.00162	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Carmustine—brain cancer	0.00016	0.00161	CcSEcCtD
Vandetanib—Dyspnoea—Temozolomide—brain cancer	0.00016	0.00161	CcSEcCtD
Vandetanib—Constipation—Carmustine—brain cancer	0.000158	0.0016	CcSEcCtD
Vandetanib—Pain—Carmustine—brain cancer	0.000158	0.0016	CcSEcCtD
Vandetanib—Dyspepsia—Temozolomide—brain cancer	0.000157	0.00159	CcSEcCtD
Vandetanib—Diarrhoea—Hydroxyurea—brain cancer	0.000157	0.00158	CcSEcCtD
Vandetanib—Decreased appetite—Temozolomide—brain cancer	0.000156	0.00157	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Temozolomide—brain cancer	0.000154	0.00156	CcSEcCtD
Vandetanib—Fatigue—Temozolomide—brain cancer	0.000154	0.00155	CcSEcCtD
Vandetanib—Loss of consciousness—Etoposide—brain cancer	0.000154	0.00155	CcSEcCtD
Vandetanib—Cough—Etoposide—brain cancer	0.000153	0.00154	CcSEcCtD
Vandetanib—Pain—Temozolomide—brain cancer	0.000153	0.00154	CcSEcCtD
Vandetanib—Constipation—Temozolomide—brain cancer	0.000153	0.00154	CcSEcCtD
Vandetanib—Convulsion—Etoposide—brain cancer	0.000152	0.00153	CcSEcCtD
Vandetanib—Hypertension—Etoposide—brain cancer	0.000151	0.00153	CcSEcCtD
Vandetanib—Dizziness—Hydroxyurea—brain cancer	0.000151	0.00153	CcSEcCtD
Vandetanib—Gastrointestinal pain—Carmustine—brain cancer	0.000151	0.00153	CcSEcCtD
Vandetanib—ABCG2—pituitary gland—brain cancer	0.000151	0.0014	CbGeAlD
Vandetanib—Chest pain—Etoposide—brain cancer	0.000149	0.0015	CcSEcCtD
Vandetanib—PDGFRB—brain—brain cancer	0.000149	0.00139	CbGeAlD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000148	0.00149	CcSEcCtD
Vandetanib—Abdominal pain—Carmustine—brain cancer	0.000146	0.00147	CcSEcCtD
Vandetanib—Body temperature increased—Carmustine—brain cancer	0.000146	0.00147	CcSEcCtD
Vandetanib—Gastrointestinal pain—Temozolomide—brain cancer	0.000146	0.00147	CcSEcCtD
Vandetanib—ABCG2—medulla oblongata—brain cancer	0.000146	0.00136	CbGeAlD
Vandetanib—Vomiting—Hydroxyurea—brain cancer	0.000146	0.00147	CcSEcCtD
Vandetanib—Rash—Hydroxyurea—brain cancer	0.000144	0.00146	CcSEcCtD
Vandetanib—Dermatitis—Hydroxyurea—brain cancer	0.000144	0.00145	CcSEcCtD
Vandetanib—Headache—Hydroxyurea—brain cancer	0.000143	0.00145	CcSEcCtD
Vandetanib—Infection—Etoposide—brain cancer	0.000142	0.00143	CcSEcCtD
Vandetanib—Abdominal pain—Temozolomide—brain cancer	0.000141	0.00143	CcSEcCtD
Vandetanib—Body temperature increased—Temozolomide—brain cancer	0.000141	0.00143	CcSEcCtD
Vandetanib—Thrombocytopenia—Etoposide—brain cancer	0.00014	0.00141	CcSEcCtD
Vandetanib—Skin disorder—Etoposide—brain cancer	0.000139	0.0014	CcSEcCtD
Vandetanib—Nausea—Hydroxyurea—brain cancer	0.000136	0.00137	CcSEcCtD
Vandetanib—ABCG2—midbrain—brain cancer	0.000133	0.00124	CbGeAlD
Vandetanib—ABL1—brain—brain cancer	0.000133	0.00123	CbGeAlD
Vandetanib—Asthenia—Carmustine—brain cancer	0.000133	0.00134	CcSEcCtD
Vandetanib—ABCG2—spinal cord—brain cancer	0.00013	0.00121	CbGeAlD
Vandetanib—Paraesthesia—Etoposide—brain cancer	0.000129	0.0013	CcSEcCtD
Vandetanib—Asthenia—Temozolomide—brain cancer	0.000128	0.00129	CcSEcCtD
Vandetanib—Dyspnoea—Etoposide—brain cancer	0.000128	0.00129	CcSEcCtD
Vandetanib—Diarrhoea—Carmustine—brain cancer	0.000127	0.00128	CcSEcCtD
Vandetanib—Pruritus—Temozolomide—brain cancer	0.000127	0.00128	CcSEcCtD
Vandetanib—ABCC1—cerebellum—brain cancer	0.000125	0.00116	CbGeAlD
Vandetanib—Decreased appetite—Etoposide—brain cancer	0.000124	0.00125	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Etoposide—brain cancer	0.000124	0.00125	CcSEcCtD
Vandetanib—Fatigue—Etoposide—brain cancer	0.000123	0.00124	CcSEcCtD
Vandetanib—ALB—brain—brain cancer	0.000123	0.00114	CbGeAlD
Vandetanib—Dizziness—Carmustine—brain cancer	0.000122	0.00123	CcSEcCtD
Vandetanib—Constipation—Etoposide—brain cancer	0.000122	0.00123	CcSEcCtD
Vandetanib—Pain—Etoposide—brain cancer	0.000122	0.00123	CcSEcCtD
Vandetanib—Diarrhoea—Temozolomide—brain cancer	0.000122	0.00123	CcSEcCtD
Vandetanib—Dizziness—Temozolomide—brain cancer	0.000118	0.00119	CcSEcCtD
Vandetanib—Vomiting—Carmustine—brain cancer	0.000118	0.00119	CcSEcCtD
Vandetanib—Gastrointestinal pain—Etoposide—brain cancer	0.000117	0.00118	CcSEcCtD
Vandetanib—Rash—Carmustine—brain cancer	0.000117	0.00118	CcSEcCtD
Vandetanib—Dermatitis—Carmustine—brain cancer	0.000117	0.00118	CcSEcCtD
Vandetanib—Headache—Carmustine—brain cancer	0.000116	0.00117	CcSEcCtD
Vandetanib—Vomiting—Temozolomide—brain cancer	0.000114	0.00115	CcSEcCtD
Vandetanib—Abdominal pain—Etoposide—brain cancer	0.000113	0.00114	CcSEcCtD
Vandetanib—Body temperature increased—Etoposide—brain cancer	0.000113	0.00114	CcSEcCtD
Vandetanib—Rash—Temozolomide—brain cancer	0.000113	0.00114	CcSEcCtD
Vandetanib—Dermatitis—Temozolomide—brain cancer	0.000113	0.00114	CcSEcCtD
Vandetanib—Headache—Temozolomide—brain cancer	0.000112	0.00113	CcSEcCtD
Vandetanib—Nausea—Carmustine—brain cancer	0.00011	0.00111	CcSEcCtD
Vandetanib—Nausea—Temozolomide—brain cancer	0.000106	0.00107	CcSEcCtD
Vandetanib—ABCG2—cerebellum—brain cancer	0.000103	0.000958	CbGeAlD
Vandetanib—Asthenia—Etoposide—brain cancer	0.000103	0.00104	CcSEcCtD
Vandetanib—Pruritus—Etoposide—brain cancer	0.000101	0.00102	CcSEcCtD
Vandetanib—ABCC1—brain—brain cancer	0.000101	0.00094	CbGeAlD
Vandetanib—Diarrhoea—Etoposide—brain cancer	9.8e-05	0.000987	CcSEcCtD
Vandetanib—Dizziness—Etoposide—brain cancer	9.47e-05	0.000954	CcSEcCtD
Vandetanib—Vomiting—Etoposide—brain cancer	9.1e-05	0.000917	CcSEcCtD
Vandetanib—Rash—Etoposide—brain cancer	9.03e-05	0.00091	CcSEcCtD
Vandetanib—Dermatitis—Etoposide—brain cancer	9.02e-05	0.000909	CcSEcCtD
Vandetanib—Headache—Etoposide—brain cancer	8.97e-05	0.000904	CcSEcCtD
Vandetanib—Nausea—Etoposide—brain cancer	8.5e-05	0.000857	CcSEcCtD
Vandetanib—ABCG2—brain—brain cancer	8.38e-05	0.000778	CbGeAlD
Vandetanib—CYP3A4—endocrine gland—brain cancer	8.16e-05	0.000758	CbGeAlD
Vandetanib—CYP3A4—central nervous system—brain cancer	7.35e-05	0.000683	CbGeAlD
Vandetanib—PDGFRB—Signaling Pathways—SPP1—brain cancer	4.98e-06	3.07e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ENO2—brain cancer	4.97e-06	3.06e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—EGFR—brain cancer	4.95e-06	3.05e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IRS2—brain cancer	4.95e-06	3.05e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PDGFRA—brain cancer	4.94e-06	3.05e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SPP1—brain cancer	4.87e-06	3e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—RELA—brain cancer	4.82e-06	2.97e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—RELA—brain cancer	4.8e-06	2.96e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SPP1—brain cancer	4.8e-06	2.96e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—ERBB2—brain cancer	4.79e-06	2.95e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—STAT3—brain cancer	4.78e-06	2.95e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—ERBB2—brain cancer	4.77e-06	2.94e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL2—brain cancer	4.75e-06	2.93e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—APC—brain cancer	4.73e-06	2.91e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—RELA—brain cancer	4.7e-06	2.9e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—RELA—brain cancer	4.7e-06	2.9e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—RELA—brain cancer	4.68e-06	2.89e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—ERBB2—brain cancer	4.67e-06	2.88e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—MYC—brain cancer	4.67e-06	2.88e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—ERBB2—brain cancer	4.67e-06	2.88e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOTCH2—brain cancer	4.67e-06	2.88e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—ERBB2—brain cancer	4.65e-06	2.87e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—RELA—brain cancer	4.65e-06	2.86e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2C9—brain cancer	4.64e-06	2.86e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—RELA—brain cancer	4.63e-06	2.85e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CCND1—brain cancer	4.63e-06	2.85e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—ERBB2—brain cancer	4.62e-06	2.85e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—ERBB2—brain cancer	4.6e-06	2.84e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CTNNB1—brain cancer	4.58e-06	2.82e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—EGFR—brain cancer	4.57e-06	2.82e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—EGFR—brain cancer	4.57e-06	2.82e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—IRS2—brain cancer	4.57e-06	2.81e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—EGFR—brain cancer	4.56e-06	2.81e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—APC—brain cancer	4.56e-06	2.81e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TP53—brain cancer	4.53e-06	2.79e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IRS2—brain cancer	4.5e-06	2.77e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HES1—brain cancer	4.48e-06	2.76e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VAV1—brain cancer	4.45e-06	2.74e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—ERBB2—brain cancer	4.41e-06	2.72e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IRS2—brain cancer	4.41e-06	2.72e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—EGFR—brain cancer	4.38e-06	2.7e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—EGFR—brain cancer	4.35e-06	2.68e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL2—brain cancer	4.34e-06	2.68e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IRS2—brain cancer	4.34e-06	2.67e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL2—brain cancer	4.33e-06	2.67e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HES1—brain cancer	4.32e-06	2.66e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PDGFRA—brain cancer	4.27e-06	2.63e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TP53—brain cancer	4.25e-06	2.62e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—ERBB2—brain cancer	4.25e-06	2.62e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL2—brain cancer	4.24e-06	2.61e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CCND1—brain cancer	4.23e-06	2.61e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL2—brain cancer	4.23e-06	2.61e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—RELA—brain cancer	4.22e-06	2.6e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL2—brain cancer	4.22e-06	2.6e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CG—brain cancer	4.2e-06	2.59e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—ERBB2—brain cancer	4.2e-06	2.59e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CTNNB1—brain cancer	4.19e-06	2.58e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL2—brain cancer	4.18e-06	2.58e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CTNNB1—brain cancer	4.18e-06	2.57e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL2—brain cancer	4.17e-06	2.57e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SPP1—brain cancer	4.14e-06	2.55e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CCND1—brain cancer	4.12e-06	2.54e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PDGFRA—brain cancer	4.11e-06	2.54e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—CTNNB1—brain cancer	4.09e-06	2.52e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CTNNB1—brain cancer	4.08e-06	2.52e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CCND1—brain cancer	4.08e-06	2.51e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—RELA—brain cancer	4.08e-06	2.51e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CTNNB1—brain cancer	4.07e-06	2.51e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—ERBB2—brain cancer	4.05e-06	2.5e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CTNNB1—brain cancer	4.04e-06	2.49e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—EGFR—brain cancer	4.04e-06	2.49e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—VEGFA—brain cancer	4.03e-06	2.49e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—APC—brain cancer	4.03e-06	2.49e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—CTNNB1—brain cancer	4.03e-06	2.48e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—RELA—brain cancer	4e-06	2.47e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—STAT3—brain cancer	3.99e-06	2.46e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SPP1—brain cancer	3.99e-06	2.46e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—ERBB2—brain cancer	3.98e-06	2.45e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—APC—brain cancer	3.98e-06	2.45e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CG—brain cancer	3.98e-06	2.45e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—IL2—brain cancer	3.96e-06	2.44e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—BSG—brain cancer	3.95e-06	2.43e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL2—brain cancer	3.94e-06	2.43e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—ERBB2—brain cancer	3.89e-06	2.4e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—APC—brain cancer	3.89e-06	2.4e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CG—brain cancer	3.89e-06	2.4e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—EGFR—brain cancer	3.88e-06	2.39e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—CTNNB1—brain cancer	3.86e-06	2.38e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—RELA—brain cancer	3.86e-06	2.38e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—APC—brain cancer	3.83e-06	2.36e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CG—brain cancer	3.83e-06	2.36e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—ERBB2—brain cancer	3.83e-06	2.36e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HES1—brain cancer	3.83e-06	2.36e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL2—brain cancer	3.8e-06	2.34e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—brain cancer	3.76e-06	2.32e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IRS2—brain cancer	3.75e-06	2.31e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—CTNNB1—brain cancer	3.72e-06	2.29e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MYC—brain cancer	3.71e-06	2.29e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CCND1—brain cancer	3.71e-06	2.28e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CG—brain cancer	3.7e-06	2.28e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—VEGFA—brain cancer	3.69e-06	2.27e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL2—brain cancer	3.67e-06	2.26e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CTNNB1—brain cancer	3.67e-06	2.26e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—ERBB2—brain cancer	3.67e-06	2.26e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—STAT3—brain cancer	3.65e-06	2.25e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PDGFRA—brain cancer	3.64e-06	2.24e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—STAT3—brain cancer	3.64e-06	2.24e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—EGFR—brain cancer	3.63e-06	2.24e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IRS2—brain cancer	3.61e-06	2.23e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL2—brain cancer	3.6e-06	2.22e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—VEGFA—brain cancer	3.6e-06	2.22e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CCND1—brain cancer	3.58e-06	2.21e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—STAT3—brain cancer	3.56e-06	2.2e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—STAT3—brain cancer	3.56e-06	2.19e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—VEGFA—brain cancer	3.56e-06	2.19e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—STAT3—brain cancer	3.55e-06	2.19e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CTNNB1—brain cancer	3.55e-06	2.19e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—ERBB2—brain cancer	3.54e-06	2.18e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SPP1—brain cancer	3.54e-06	2.18e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—STAT3—brain cancer	3.52e-06	2.17e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—STAT3—brain cancer	3.51e-06	2.16e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CTNNB1—brain cancer	3.48e-06	2.14e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL2—brain cancer	3.47e-06	2.14e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—RELA—brain cancer	3.41e-06	2.1e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—CTNNB1—brain cancer	3.41e-06	2.1e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—IDH1—brain cancer	3.4e-06	2.09e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MYC—brain cancer	3.39e-06	2.09e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—ERBB2—brain cancer	3.39e-06	2.09e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—VEGFA—brain cancer	3.36e-06	2.07e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—STAT3—brain cancer	3.36e-06	2.07e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CTNNB1—brain cancer	3.35e-06	2.07e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—EGFR—brain cancer	3.32e-06	2.05e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—APC—brain cancer	3.31e-06	2.04e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CG—brain cancer	3.31e-06	2.04e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—EGFR—brain cancer	3.31e-06	2.04e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MYC—brain cancer	3.31e-06	2.04e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MYC—brain cancer	3.27e-06	2.02e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—STAT3—brain cancer	3.24e-06	2e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—EGFR—brain cancer	3.24e-06	2e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EGFR—brain cancer	3.24e-06	1.99e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—EGFR—brain cancer	3.22e-06	1.99e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—CTNNB1—brain cancer	3.21e-06	1.98e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EGFR—brain cancer	3.2e-06	1.97e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—STAT3—brain cancer	3.2e-06	1.97e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IRS2—brain cancer	3.2e-06	1.97e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CG—brain cancer	3.19e-06	1.97e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—APC—brain cancer	3.19e-06	1.97e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—EGFR—brain cancer	3.19e-06	1.97e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—ERBB2—brain cancer	3.13e-06	1.93e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MYC—brain cancer	3.12e-06	1.93e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—VEGFA—brain cancer	3.12e-06	1.92e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—RELA—brain cancer	3.11e-06	1.91e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—CTNNB1—brain cancer	3.09e-06	1.91e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—STAT3—brain cancer	3.09e-06	1.91e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ERBB2—brain cancer	3.09e-06	1.9e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL2—brain cancer	3.07e-06	1.89e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—EGFR—brain cancer	3.06e-06	1.88e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—brain cancer	3.05e-06	1.88e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—RELA—brain cancer	3.04e-06	1.87e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—STAT3—brain cancer	3.03e-06	1.87e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ERBB2—brain cancer	3.02e-06	1.86e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—MYC—brain cancer	3.01e-06	1.86e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—RELA—brain cancer	2.99e-06	1.85e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ERBB2—brain cancer	2.98e-06	1.83e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MYC—brain cancer	2.97e-06	1.83e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—STAT3—brain cancer	2.97e-06	1.83e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CTNNB1—brain cancer	2.97e-06	1.83e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—EGFR—brain cancer	2.95e-06	1.82e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—STAT3—brain cancer	2.92e-06	1.8e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EGFR—brain cancer	2.91e-06	1.79e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MYC—brain cancer	2.87e-06	1.77e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APC—brain cancer	2.82e-06	1.74e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CG—brain cancer	2.82e-06	1.74e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EGFR—brain cancer	2.81e-06	1.73e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—STAT3—brain cancer	2.8e-06	1.73e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL2—brain cancer	2.8e-06	1.72e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—brain cancer	2.79e-06	1.72e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MYC—brain cancer	2.76e-06	1.7e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CTNNB1—brain cancer	2.74e-06	1.69e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL2—brain cancer	2.74e-06	1.69e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCND1—brain cancer	2.73e-06	1.68e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—brain cancer	2.72e-06	1.67e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CTNNB1—brain cancer	2.7e-06	1.66e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EGFR—brain cancer	2.7e-06	1.66e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—STAT3—brain cancer	2.7e-06	1.66e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL2—brain cancer	2.7e-06	1.66e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—brain cancer	2.69e-06	1.66e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ENO2—brain cancer	2.68e-06	1.65e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCND1—brain cancer	2.67e-06	1.65e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—EGFR—brain cancer	2.66e-06	1.64e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CTNNB1—brain cancer	2.64e-06	1.63e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCND1—brain cancer	2.63e-06	1.62e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CTNNB1—brain cancer	2.6e-06	1.6e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—brain cancer	2.6e-06	1.6e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—STAT3—brain cancer	2.59e-06	1.59e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RELA—brain cancer	2.59e-06	1.59e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ERBB2—brain cancer	2.57e-06	1.58e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—brain cancer	2.54e-06	1.57e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—brain cancer	2.51e-06	1.54e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RELA—brain cancer	2.49e-06	1.54e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ERBB2—brain cancer	2.48e-06	1.53e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—brain cancer	2.45e-06	1.51e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—brain cancer	2.44e-06	1.5e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—brain cancer	2.39e-06	1.47e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—brain cancer	2.38e-06	1.47e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—brain cancer	2.36e-06	1.45e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—brain cancer	2.35e-06	1.45e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—brain cancer	2.35e-06	1.45e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—brain cancer	2.33e-06	1.44e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—brain cancer	2.33e-06	1.43e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—brain cancer	2.3e-06	1.42e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—brain cancer	2.29e-06	1.41e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CG—brain cancer	2.28e-06	1.41e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—brain cancer	2.27e-06	1.4e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—brain cancer	2.27e-06	1.4e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CTNNB1—brain cancer	2.25e-06	1.39e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—brain cancer	2.25e-06	1.38e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—brain cancer	2.22e-06	1.37e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RELA—brain cancer	2.21e-06	1.36e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ERBB2—brain cancer	2.19e-06	1.35e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—brain cancer	2.19e-06	1.35e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—brain cancer	2.19e-06	1.35e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—brain cancer	2.17e-06	1.34e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CTNNB1—brain cancer	2.17e-06	1.34e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—brain cancer	2.14e-06	1.32e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—brain cancer	2.14e-06	1.32e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—brain cancer	2.11e-06	1.3e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—brain cancer	2.09e-06	1.29e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—brain cancer	2.06e-06	1.27e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—brain cancer	1.99e-06	1.22e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—brain cancer	1.98e-06	1.22e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—brain cancer	1.96e-06	1.21e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—brain cancer	1.94e-06	1.19e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CTNNB1—brain cancer	1.92e-06	1.18e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—brain cancer	1.91e-06	1.18e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—brain cancer	1.89e-06	1.16e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—brain cancer	1.82e-06	1.12e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—brain cancer	1.8e-06	1.11e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—brain cancer	1.76e-06	1.08e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—brain cancer	1.76e-06	1.08e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—brain cancer	1.73e-06	1.07e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—brain cancer	1.72e-06	1.06e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—brain cancer	1.69e-06	1.04e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—brain cancer	1.67e-06	1.03e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—brain cancer	1.55e-06	9.58e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—brain cancer	1.52e-06	9.37e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—brain cancer	1.5e-06	9.22e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—brain cancer	1.44e-06	8.89e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—brain cancer	1.28e-06	7.87e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CG—brain cancer	1.23e-06	7.59e-06	CbGpPWpGaD
